Genomic imbalances associated with acquired resistance to platinum analogues

Related Experiment Video

Updated: Oct 20, 2026

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

B Leyland-Jones1, L R Kelland, K R Harrap

  • 1Department of Oncology, McGill University, Montreal, Quebec, Canada. leylandj@med.mcgill.ca

The American Journal of Pathology
|July 8, 1999
PubMed

Insights

Researchers identified DNA copy number changes in ovarian cancer cells resistant to platinum drugs like cisplatin. Amplifications on chromosomes 4q and 6q were most common, potentially harboring genes crucial for drug resistance and future cancer therapies.

Area of Science:

  • Oncology
  • Molecular Cytogenetics
  • Cancer Genomics

Background:

  • Acquired resistance to platinum-based chemotherapy, including cisplatin and its analogues (JM216, AMD473), is a significant challenge in ovarian cancer treatment.
  • Understanding the genetic underpinnings of this resistance is crucial for developing more effective therapeutic strategies.

Purpose of the Study:

  • To investigate DNA copy number alterations associated with acquired resistance to cisplatin and its analogues in human tumor cell lines.
  • To identify specific chromosomal regions and potential genes involved in platinum analogue resistance mechanisms.

Main Methods:

  • Utilized comparative genomic hybridization (CGH), a molecular cytogenetic technique, to analyze DNA gains and losses in resistant cell lines.
  • Established and characterized a panel of human tumor cell lines, predominantly ovarian, with acquired resistance to cisplatin, JM216, and AMD473.

Main Results:

  • Frequent DNA amplifications observed on chromosomes 4q (5/7) and 6q (5/7), followed by 5q (3/7) in resistant cell lines.
  • Defined four minimal common overrepresented regions on 4q and 6q, suggesting potential loci for resistance genes.
  • Observed amplification of 12q in cell lines with increased DNA repair as a resistance mechanism, linking specific aberrations to resistance pathways.

Conclusions:

  • Comparative genomic hybridization studies identified distinct chromosomal aberrations correlating with platinum analogue resistance mechanisms.
  • These findings highlight potential novel genes on amplified chromosomal regions that could serve as therapeutic targets for overcoming drug resistance in cancer.

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...